Dual‐Targeting Peptide‐Guided Approach for Precision Delivery and Cancer Monitoring by Using a Safe Upconversion Nanoplatform

News

A research team led by Professor Gary Wong Ka-Leung (centre), Dr Lung Hong Lok (right) and Dr Law Ga-lai develop a novel dual-targeting drug for treating cancers associated with EBV.
02 Mar 2021
Hong Kong Baptist University (HKBU)
A Hong Kong Baptist University-led (HKBU) research team has developed a novel drug which has the potential to become a next-generation treatment for cancers associated with Epstein–Barr virus (EBV).